Revisiones en Cáncer 00018 / http://dx.doi.org/10.20960/revcancer.00018
Resumen| PDF

Revisión

Futuro y líneas de investigación clínica del cáncer de mama luminal metastásico


Clara García González, Vega Iranzo González-Cruz

Prepublicado: 2023-07-12
Publicado: 2023-07-17

Logo Descargas   Número de descargas: 6095      Logo Visitas   Número de visitas: 405      Citas   Citas: 0

Compártelo:


Uno de los grandes avances acontecidos en los últimos años dentro del cáncer de mama luminal metastásico lo protagoniza la llegada de los inhibidores de cinasa dependientes de ciclina. En la actualidad constituyen el estándar de tratamiento, en combinación con hormonoterapia en primera línea. Gracias a la profundización en el conocimiento de la biología molecular, la investigación en este tumor no deja de crecer. Así, en caso de progresión, cada vez hay más opciones terapéuticas dirigidas a distintas dianas terapéuticas, como PI3KA o ESR1. Por otra parte, la determinación de los mecanismos de resistencia a los tratamientos recibidos previamente nos puede guiar en la mejor decisión terapéutica. En estos momentos, son muchas las líneas de investigación abiertas, como el papel del retratamiento con inhibidores de ciclina tras la progresión, los degradadores y moduladores selectivos del receptor de estrógeno orales, el PROTAC®, o los anticuerpos conjugados que revisaremos a continuación.

Palabras Clave: Cáncer de mama luminal metastásico. Inhibidores de cinasas dependientes de ciclina. Mecanismos de resistencia. Degradador selectivo del receptor de estrógeno. Modulador selectivo del receptor de estrógeno. PROTAC®.



(1) GLOBOCAN 2020. Breast cancer estimated Incidence, Mortality and Prevalence Worldwide in 2020. Available at https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf (acceso 16 de junio 2021).
(2) Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer [Internet]. 2017;8(16):3131–41. Disponible en: http://dx.doi.org/10.7150/jca.18457
DOI: 10.7150/jca.18457
(3) Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929–43
(4) Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol [Internet]. 2021;39(35):3959–77. Disponible en: http://dx.doi.org/10.1200/JCO.21.01392
DOI: 10.1200/JCO.21.01392
(5) Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol [Internet]. 2021;32(12):1475–95. Disponible en: http://dx.doi.org/10.1016/j.annonc.2021.09.019
DOI: 10.1016/j.annonc.2021.09.019
(6) National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Breast Cancer. 2023;(2). Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (acceso 8 de febrero 2023).
(7) Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol [Internet]. 2019;21(1):31–45. Disponible en: http://dx.doi.org/10.1007/s12094-018-02010-w
DOI: 10.1007/s12094-018-02010-w
(8) Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res [Internet]. 2009;11(5):R77. Disponible en: http://dx.doi.org/10.1186/bcr2419
DOI: 10.1186/bcr2419
(9) Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther [Internet]. 2004;3(11):1427–38. Disponible en: http://dx.doi.org/10.1158/1535-7163.1427.3.11
DOI: 10.1158/1535-7163.1427.3.11
(10) Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res [Internet]. 2016;18(1):17. Disponible en: http://dx.doi.org/10.1186/s13058-015-0661-5
DOI: 10.1186/s13058-015-0661-5
(11) O’Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov [Internet]. 2018;8(11):1390–403. Disponible en: http://dx.doi.org/10.1158/2159-8290.CD-18-0264
DOI: 10.1158/2159-8290.CD-18-0264
(12) Finn RS, Martin M, Rugo HS, Jones SE, Im S-A, Gelmon KA, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol [Internet]. 2016;34(15_suppl):507–507. Disponible en: http://dx.doi.org/10.1200/jco.2016.34.15_suppl.507
DOI: 10.1200/JCO.2016.34.15_suppl.507
(13) Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2− ABC)
(14) Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol [Internet]. 2019;30(11):1842. Disponible en: http://dx.doi.org/10.1093/annonc/mdz215
DOI: 10.1093/annonc/mdz215
(15) Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med [Internet]. 2022;386(10):942–50. Disponible en: http://dx.doi.org/10.1056/NEJMoa2114663
DOI: 10.1056/NEJMoa2114663
(16) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol [Internet]. 2021;32(8):1015–24. Disponible en: http://dx.doi.org/10.1016/j.annonc.2021.05.353
DOI: 10.1016/j.annonc.2021.05.353
(17) Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med [Internet]. 2019;381(4):307–16. Disponible en: http://dx.doi.org/10.1056/NEJMoa1903765
DOI: 10.1056/NEJMoa1903765
(18) Lu Y-S, Im S-A, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial. Clin Cancer Res [Internet]. 2022;28(5):851–9. Disponible en: http://dx.doi.org/10.1158/1078-0432.CCR-21-3032
DOI: 10.1158/1078-0432.CCR-21-3032
(19) Lu Y-S; Bin Mohd Mahidin EI; Azim H; Eralp Y; Yap Y-S; Im S-A, et al. Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Presented at SABCS 2022. Abstract GS1-10.
DOI: 10.1158/1538-7445.SABCS22-GS1-10
(20) Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res [Internet]. 2017;23(17):5218–24. Disponible en: http://dx.doi.org/10.1158/1078-0432.CCR-17-0754
DOI: 10.1158/1078-0432.CCR-17-0754
(21) Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial: A randomized clinical trial. JAMA Oncol [Internet]. 2020;6(1):116–24. Disponible en: http://dx.doi.org/10.1001/jamaoncol.2019.4782
DOI: 10.1001/jamaoncol.2019.4782
(22) Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol [Internet]. 2017;35(32):3638–46. Disponible en: http://dx.doi.org/10.1200/JCO.2017.75.6155
DOI: 10.1200/JCO.2017.75.6155
(23) Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH, et al. LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol [Internet]. 2022;33:S1384. Disponible en: http://dx.doi.org/10.1016/j.annonc.2022.08.009
DOI: 10.1016/j.annonc.2022.08.009
(24) Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Safety analysis of MONARCH 2 and MONARCH 3. Oncologist [Internet]. 2021;26(1):e53–65. Disponible en: http://dx.doi.org/10.1002/onco.13531
DOI: 10.1002/onco.13531
(25) D’Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol [Internet]. 2018;11(1). Disponible en: http://dx.doi.org/10.1186/s13045-018-0620-6
DOI: 10.1186/s13045-018-0620-6
(26) Cetin B, Wabl CA, Gumusay O. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncol [Internet]. 2022;18(9):1143–57. Disponible en: http://dx.doi.org/10.2217/fon-2021-0842
DOI: 10.2217/fon-2021-0842
(27) McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, et al. Mechanisms of resistance to CDK4/6 inhibitors: Potential implications and biomarkers for clinical practice. Front Oncol [Internet]. 2019;9:666. Disponible en: http://dx.doi.org/10.3389/fonc.2019.00666
DOI: 10.3389/fonc.2019.00666
(28) O’Brien NA, Tomaso ED, Ayala R, Tong L, Issakhanian S, Linnartz R, et al. Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Res [Internet]. 2014;74(19_Supplement):4756–4756. Disponible en: http://dx.doi.org/10.1158/1538-7445.am2014-4756
DOI: 10.1158/1538-7445.AM2014-4756
(29) Mayer EL, Wander SA, Regan MM, DeMichele A, Forero-Torres A, Rimawi MF, et al. Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. J Clin Oncol [Internet]. 2018;36(15_suppl):TPS1104–TPS1104. Disponible en: http://dx.doi.org/10.1200/jco.2018.36.15_suppl.tps1104
DOI: 10.1200/JCO.2018.36.15_suppl.TPS1104
(30) Kalinsky K, Accordino MK, Chiuzan C,Mundi PS, Trivedi MS, Novik Y. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Presented at ASCO 2022 Annual Meeting II.
DOI: 10.1200/JCO.2022.40.17_suppl.LBA1004
(31) Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med [Internet]. 2012;366(6):520–9. Disponible en: http://dx.doi.org/10.1056/NEJMoa1109653
DOI: 10.1056/NEJMoa1109653
(32) Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, et al. A phase Ib study of alpelisib (BYL719), a PI3Kα-specific inhibitor, with letrozole in ER+/HER2- metastatic breast cancer. Clin Cancer Res [Internet]. 2017;23(1):26–34. Disponible en: http://dx.doi.org/10.1158/1078-0432.CCR-16-0134
DOI: 10.1158/1078-0432.CCR-16-0134
(33) André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2019 May 16;380(20):1929–40
DOI: 10.1056/NEJMoa1813904
(34) André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol [Internet]. 2021;32(2):208–17. Disponible en: http://dx.doi.org/10.1016/j.annonc.2020.11.011
DOI: 10.1016/j.annonc.2020.11.011
(35) Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz Borrego M, Neven P, et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. J Clin Oncol [Internet]. 2020;38(15_suppl):1006–1006. Disponible en: http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1006
DOI: 10.1200/JCO.2020.38.15_suppl.1006
(36) Jones RH, Carucci M, Casbard AC, Butler R, Alchami F, Bale CJ, et al. Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. J Clin Oncol [Internet]. 2019;37(15_suppl):1005–1005. Disponible en: http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1005
DOI: 10.1200/JCO.2019.37.15_suppl.1005
(37) Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol [Internet]. 2022;23(7):851–64. Disponible en: http://dx.doi.org/10.1016/S1470-2045(22)00284-4
DOI: 10.1016/S1470-2045(22)00284-4
(38) Turner N, Oliveira M, Howell S, et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the Phase III CAPItello-291 trial. Presented at SABCS 2022. December 6-10, 2022. Abstract GS3-04.
DOI: 10.1158/1538-7445.SABCS22-GS3-04
(39) Bedard PL, Accordino MK, Cervantes A, Gambardella V, Hamilton EP, Italiano A, et al. Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC). J Clin Oncol [Internet]. 2022;40(16_suppl):1052–1052. Disponible en: http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1052
DOI: 10.1200/JCO.2022.40.16_suppl.1052
(40) Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003(2):CD002747.
DOI: 10.1002/14651858.CD002747
(41) Hernando C, Ortega-Morillo B, Tapia M, Moragón S, Martínez MT, Eroles P, et al. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: Present and future from a clinical perspective. Int J Mol Sci [Internet]. 2021;22(15):7812. Disponible en: http://dx.doi.org/10.3390/ijms22157812
DOI: 10.3390/ijms22157812
(42) Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol [Internet]. 2010;28(30):4594–600. Disponible en: http://dx.doi.org/10.1200/JCO.2010.28.8415
DOI: 10.1200/JCO.2010.28.8415
(43) Bardia A, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier M-A, et al. Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. Cancer Res [Internet]. 2022;82(4_Supplement):GS2-02-GS2-02. Disponible en: http://dx.doi.org/10.1158/1538-7445.sabcs21-gs2-02
DOI: 10.1158/1538-7445.SABCS21-GS2-02
(44) Chandarlapaty S, Linden HM, Neven P, Petrakova K, Bardia A, Kabos P, et al. Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer. Cancer Res [Internet]. 2022;82(4_Supplement):P1-17-11-P1-17–11. Disponible en: http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-17-11
DOI: 10.1158/1538-7445.SABCS21-P1-17-11
(45) Jhaveri KL, Lim E, Hamilton EP, Saura C, Meniawy T, Jeselsohn R, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. J Clin Oncol [Internet]. 2021;39(15_suppl):1050–1050. Disponible en: http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1050
DOI: 10.1200/JCO.2021.39.15_suppl.1050
(46) Oliveira M, Hamilton EP, Incorvati J, Bermejo de la Heras B, Calvo E, García-Corbacho J, et al. Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. J Clin Oncol [Internet]. 2022;40(16_suppl):1032–1032. Disponible en: http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1032
DOI: 10.1200/JCO.2022.40.16_suppl.1032
(47) Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, et al. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res [Internet]. 2013;15(3):R47. Disponible en: http://dx.doi.org/10.1186/bcr3439
DOI: 10.1186/bcr3439
(48) Damodaran S, Plourde PV, Moore HCF, Anderson IC, Portman DJ. Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies. J Clin Oncol [Internet]. 2022;40(16_suppl):1022–1022. Disponible en: http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1022
DOI: 10.1200/JCO.2022.40.16_suppl.1022
(49) Hamilton EP, Schott AF, Nanda R, Lu H, Keung CF, Gedrich R, et al. ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study. J Clin Oncol [Internet]. 2022;40(16_suppl):TPS1120–TPS1120. Disponible en: http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps1120
DOI: 10.1200/JCO.2022.40.16_suppl.TPS1120
(50) Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O’Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol [Internet]. 2020;31(12):1709–18. Disponible en: http://dx.doi.org/10.1016/j.annonc.2020.09.004
DOI: 10.1016/j.annonc.2020.09.004
(51) Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, et al. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol [Internet]. 2020;16(12):705–15. Disponible en: http://dx.doi.org/10.2217/fon-2020-0163
DOI: 10.2217/fon-2020-0163
(52) Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, et al. LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol [Internet]. 2022;33:S1386. Disponible en: http://dx.doi.org/10.1016/j.annonc.2022.08.012
DOI: 10.1016/j.annonc.2022.08.012
(53) Cortés J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med [Internet]. 2022;386(12):1143–54. Disponible en: http://dx.doi.org/10.1056/NEJMoa2115022
DOI: 10.1056/NEJMoa2115022
(54) Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med [Internet]. 2022;387(1):9–20. Disponible en: http://dx.doi.org/10.1056/NEJMoa2203690
DOI: 10.1056/NEJMoa2203690
(55) Bidard FC, et al. Circulating tumor cells-driven choice of first line therapy for HR+ HER2-metastatic breast cancer. Overall survival analysis of the phase 3 STIC CTC trial. Abstract GS3-09, SABCS 2022, 06–10 December.
DOI: 10.1158/1538-7445.SABCS22-GS3-09

Artículos más populares

Revisión: Primera línea de tratamiento sistémico del cáncer de mama metastásico triple negativo

El cáncer de mama triple negativo (CMTN) se asocia...

Publicado: 2023-03-20

Revisión: Primera línea de tratamiento paliativo del cáncer de mama HER2+

Aproximadamente un 20 % de los tumores de mama tie...

Publicado: 2023-07-12

Revisión: Oligometástasis en cáncer de mama: estrategias y perspectivas para el control local del tumor primario y de las metástasis

El cáncer de mama metastásico, identificado en el...

Publicado: 2023-04-27

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.